Hyperlipidemia, Familial CombinedHyperlipidemiasHypertensionHypolipidemic AgentsTriglyceridesHypertension, PulmonaryCholesterolLipidsXanthomatosisCholesterol, LDLPeriarthritisHypercholesterolemiaRisk FactorsAnticholesteremic AgentsLipoproteinsCholesterol, HDLFenofibrateHydroxymethylglutaryl-CoA Reductase InhibitorsDiabetes MellitusBlood PressureHypertension, RenalHyperlipoproteinemia Type IIHypertension, PortalApolipoproteins BObesityCardiovascular DiseasesAntihypertensive AgentsLipoproteins, VLDLAzetidinesSimvastatinLipoproteins, LDLHypertriglyceridemiaHypertension, RenovascularDiabetes Mellitus, Type 2Diabetes ComplicationsPrevalenceBlood GlucoseHyperlipoproteinemia Type IVCoronary DiseaseApolipoproteins EHypertension, MalignantLipid MetabolismApolipoproteins CTreatment OutcomeApolipoprotein E2Prospective StudiesApolipoprotein C-IIILipoprotein LipaseAge FactorsArteriosclerosisInsulinCase-Control StudiesRegression AnalysisBody Mass IndexMalaysiaFollow-Up StudiesLiverApolipoproteinsDisease Models, AnimalCholesterol, VLDLAtherosclerosisDrug Therapy, CombinationCross-Sectional StudiesTendinopathyDietary FatsDouble-Blind MethodGynostemmaMyocardial InfarctionBody WeightBiological MarkersKidney TransplantationHypertension, Pregnancy-InducedReceptors, LDLArthritisDyslipidemiasPractice Guidelines as TopicInsulin ResistanceHyperlipoproteinemia Type IIITime FactorsMice, Inbred C57BLKidneySmokingPoloxamerHeptanoic AcidsDiet, AtherogenicOcular HypertensionApolipoprotein A-IPulmonary ArteryRats, Sprague-DawleyCholesterol, DietaryRetrospective StudiesFatty LiverPostprandial PeriodBezafibratePyrrolesMice, KnockoutEpichlorohydrinRats, Inbred SHRApolipoproteins ARenin